NYSE: LLY
ELI LILLY & Co Stock Forecast, Predictions & Price Target

Analyst price target for LLY

Based on 8 analysts offering 12 month price targets for ELI LILLY & Co.
Min Forecast
$144.00+9.66%%
Avg Forecast
$175.38+33.56%%
Max Forecast
$200.00+52.31%%

Should I buy or sell LLY stock?

Strong Buy
Strong Buy
9 analysts 75%%
Buy
0 analysts 0%%
Hold
3 analysts 25%%
Sell
0 analysts 0%%
Strong Sell
0 analysts 0%%

Forecast return on equity

Is LLY forecast to generate an efficient return?
Company
203.11%%
Industry
65.68%%
Market
-6.64%%
LLY's Return on Equity is forecast to be high in 4 years (203.11%%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is LLY forecast to generate an efficient return on assets?
Company
22.31%%
Industry
15.48%%
Market
11.54%%
LLY is forecast to generate higher Return on Assets (22.31%%) than the US Drug Manufacturers - General industry average (15.48%%)
Forecast

LLY earnings per share forecast

What is LLY's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$7.29+18.47%%
Avg 2 year Forecast
$7.99+29.87%%
Avg 3 year Forecast
$8.97+45.91%%
LLY's earnings are forecast to grow at a rate of 13.04%% per year, which is not exceptional
Forecast

LLY revenue forecast

What is LLY's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$23.8B+2.52%%
Avg 2 year Forecast
$26.0B+11.81%%
Avg 3 year Forecast
$27.7B+19.45%%
LLY's revenue is forecast to grow at a rate of 6.18%% per year, which is not exceptional
Forecast

LLY earnings growth forecast

How is LLY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
13.04%%
Industry
18.94%%
Market
13.11%%
LLY's earnings are forecast to grow slower (13.04%% per year) than the US Drug Manufacturers - General industry average (18.94%%)
Forecast
LLY's earnings are forecast to grow slower (13.04%% per year) than the US market average (13.11%%)
Forecast

LLY revenue growth forecast

How is LLY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
6.18%%
Industry
6.35%%
Market
5.29%%
LLY's revenues are forecast to grow slower (6.18%% per year) than the US Drug Manufacturers - General industry average (6.35%%)
Forecast
LLY's revenues are forecast to grow faster (6.18%% per year) than the US market average (5.29%%)
Forecast

ELI LILLY & Stock Forecast FAQ

The consensus among 12 Wall Street analysts covering (NYSE: LLY) stock is to Strong Buy LLY stock.

Out of 12 analysts, 9 (75%%) are recommending LLY as a Strong Buy, 0 (0%%) are recommending LLY as a Buy, 3 (25%%) are recommending LLY as a Hold, 0 (0%%) are recommending LLY as a Sell, and 0 (0%%) are recommending LLY as a Strong Sell.
According to 8 Wall Street analysts that have issued a 1 year LLY price target, the average LLY price target is $175.38, with the highest LLY stock price forecast at $200.00 and the lowest LLY stock price forecast at $144.00.

On average, Wall Street analysts predict that ELI LILLY &'s share price could reach $175.38 by Oct 26, 2021. The average ELI LILLY & stock price prediction forecasts a potential upside of 33.56%% from the current LLY share price of $131.31.
(NYSE: LLY) ELI LILLY &'s forecast annual earnings growth rate of 13.04%% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 18.94%%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 13.11%%.

ELI LILLY &'s earnings in 2020 is $5,572,600,000.On average, 7 Wall Street analysts forecast LLY's earnings for 2020 to be $6,968,556,189, with the lowest LLY earnings forecast at $6,886,586,678, and the highest LLY earnings forecast at $7,077,880,753. On average, 7 Wall Street analysts forecast LLY's earnings for 2021 to be $7,639,424,508, with the lowest LLY earnings forecast at $7,001,363,123, and the highest LLY earnings forecast at $7,986,527,606.

In 2022, LLY is forecast to generate $8,582,695,589 in earnings, with the lowest earnings forecast at $8,378,680,459 and the highest earnings forecast at $8,694,315,681.
(NYSE: LLY) ELI LILLY &'s forecast annual revenue growth rate of 6.18%% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.35%%, and while it is forecast to beat the US market's average forecast revenue growth rate of 5.29%%.

ELI LILLY &'s revenue in 2020 is $23,213,800,000.On average, 3 Wall Street analysts forecast LLY's revenue for 2020 to be $22,763,060,382,047, with the lowest LLY revenue forecast at $22,690,671,834,882, and the highest LLY revenue forecast at $22,805,123,079,596. On average, 3 Wall Street analysts forecast LLY's revenue for 2021 to be $24,826,083,761,528, with the lowest LLY revenue forecast at $24,688,795,830,213, and the highest LLY revenue forecast at $24,913,183,779,484.

In 2022, LLY is forecast to generate $26,521,618,789,973 in revenue, with the lowest revenue forecast at $26,364,904,945,402 and the highest revenue forecast at $26,606,136,337,924.
(NYSE: LLY) ELI LILLY &'s current Earnings Per Share (EPS) is $6.15. On average, analysts forecast that LLY's EPS will be $7.29 for 2020, with the lowest EPS forecast at $7.20, and the highest EPS forecast at $7.40. On average, analysts forecast that LLY's EPS will be $7.99 for 2021, with the lowest EPS forecast at $7.32, and the highest EPS forecast at $8.35. In 2022, LLY's EPS is forecast to hit $8.97 (min: $8.76, max: $9.09).
(NYSE: LLY) forecast ROE is 203.11%%, which is considered strong.
(NYSE: LLY) forecast ROA is 22.31%%, which is higher than the forecast US Drug Manufacturers - General industry average of 15.48%%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics